Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function
Open accessThe DOI matches its Crossref record; 111 of the 112 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 (GLP-1) is a hormone secreted predominantly by the distal small intestine and colon and released in response to enteral nutrient exposure. GLP-1-based therapies are now used widely in the management of type 2 diabetes and have the potential to be effective antiobesity agents. Although widely known as an incretin hormone, there is a growing body of evidence that GLP-1 also acts as an enterogastrone, with profound effects on the gastrointestinal motor system. Moreover, the effects of GLP-1 on gastrointestinal motility appear to be pivotal to its effect of reducing postprandial glycaemic excursions and may, potentially, represent the dominant mechanism. This review summarizes current knowledge of the enterogastrone properties of GLP-1, focusing on its effects on gut motility at physiological and pharmacological concentrations, and the motor actions of incretin-based therapies. While of potential importance, the inhibitory action of GLP-1 on gastric acid secretion is beyond the scope of this paper.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Blood glucose (a) and plasma insulin (b) concentrations during IV infusion of GLP-1, at 0.3 and 0.9 pmol/kg/minutes, or 0.9% saline, in 10 healthy humans. Data are means ± SEM. *GLP-1 0.3 and 0.9 versus saline: P < .05; #GLP-1 0.9 versus GLP-1 0.3: P < .05 (adapted from Little et al. 2006 [19], and used with permission from the publisher).](https://figures.cochat.ai/paper-figures/12ab264a4ad24a26a6cba2d995beab18/effects-of-glp-1-and-incretin-based-therapies-on-gastrointestinal-motor-function-figure-1.jpg)
![Figure 2 Relationship between the area under the plasma glucose concentration curve between 0 and 30 minutes and the retention of the meal in the stomach at 30 minutes (r = 0.65, P < .01) (adapted from Horowitz et al. 1993 [45] and used with the permission of the publisher).](https://figures.cochat.ai/paper-figures/9c0d556b035e4aa9a9b1a00b73ec14a4/effects-of-glp-1-and-incretin-based-therapies-on-gastrointestinal-motor-function-figure-2.jpg)
![Figure 3 Gastric emptying curves for the solid and liquid components of a meal for the total, proximal, and distal stomach during IV infusion of GLP-1 at 0.3 and 0.9 pmol/kg/minutes, or 0.9% saline, in 10 healthy humans. Data are means ± SEM. *GLP-1 0.3 and 0.9 versus saline: P < .05; #GLP-1 0.9 versus GLP-1 0.3: P < .05 (adapted from Little et al. 2006 [19] and used with permission from the publisher).](https://figures.cochat.ai/paper-figures/ce9fce815c1442429bc48b6a23974b19/effects-of-glp-1-and-incretin-based-therapies-on-gastrointestinal-motor-function-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 RAs delay gastric emptying by inhibiting gastrointestinal motility through both PNS and CNS.”
From Delayed gastric emptying induced by glucagon-like peptide-1 receptor agonists and its implications for perioperative risk during anesthesia (2026) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, this promotes fundic relaxation, decreases peristalsis in the gastric antrum and duodenum, and increases pyloric sphincter tone, thereby delaying the transfer of gastric contents into the duodenum [29].”
From Delayed gastric emptying induced by glucagon-like peptide-1 receptor agonists and its implications for perioperative risk during anesthesia (2026) · cites this paper as [29]
Experimental — accuracy not yet measuredIn the citing paper
“Constipation tended to last longer, and may be because of the effects of GLP‐1RAs on GI motility. 22”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 2×
“This has provided the rationale for the development, and subsequent widespread use, of synthetic longer-acting analogues, such as exenatide and liraglutide (the two approved GLP-1 analogues), and DPP-4 inhibitors, like sitagliptin and vildagliptin, to improve glycaemic control in type 2 diabetic patients [27].”
BackgroundThe Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
The mechanism of pancreatic secretion
Bayliss, W. M., & Starling, E. H. (1902) · The Journal of Physiology · doi:10.1113/jphysiol.1902.sp000920 · Cited by 1,269
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · cited 2×
“While these could relate to its effects on gastric motor function, and antral distension in particular [35, 36, 97], the occurrence of adverse effects seems not to relate closely to the delay in gastric emptying [81, 96], and it is possible that central mechanisms are important.”
BackgroundGut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1.
Jang, H.-J., Kokrashvili, Z., Theodorakis, M. J., Carlson, O. D., Kim, B.-J., Zhou, J., Kim, H. H., Xu, X., Chan, S. L., Juhaszova, M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706890104 · Cited by 995
Postprandial Hyperglycemia and Diabetes Complications
Ceriello, A. (2005) · Diabetes · doi:10.2337/diabetes.54.1.1 · Cited by 945 · cited 1×
“Postprandial hyperglycaemia is being increasingly recognised as an independent predictor of cardiovascular mortality in both diabetic and nondiabetic populations [55, 56].”
BackgroundVilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
Plasma Insulin Response to Oral and Intravenous Glucose Administration1
ELRICK, H., STIMMLER, L., HLAD, C. J., & ARAI, Y. (1964) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-24-10-1076 · Cited by 857
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824 · cited 1×
“The insulinotropic property of GIP is markedly diminutesished in type 2 diabetic patients [89–91], probably in part as an effect of hyperglycaemia.”
Background
Research works printed but not linked: 14
- 1964, The Lancet, 284, 20
- 1997, American Journal of Physiology, 273, E981
- 2010, Neurogastroenterology & Motility, 22, article e1315, 1191
- 2004, Diabetes, Nutrition & Metabolism, 17, 336
- 1999, American Journal of Physiology, 277, G1217
- 1990, American Journal of Physiology, 259, G1031
- 1998, American Journal of Physiology, 275, R1293
- 1998, American Journal of Physiology, 275, R1308
- 1996, Journal of Nuclear Medicine, 37, 1643
- 1996, American Journal of Physiology, 271, G814
- 2002, American Journal of Physiology, 282, G424
- 2000, American Journal of Physiology, 278, G924
- 2010, Journal of Drug Design, Development and Therapy, 4, 279
- 2003, Diabetes, 52, A322
Cited by
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Microbial Modulation of Energy Availability in the Colon Regulates Intestinal Transit
Wichmann, A., Allahyar, A., Greiner, T. U., Plovier, H., Lundén, G. Ö., Larsson, T., Drucker, D. J., Delzenne, N. M., Cani, P. D., & Bäckhed, F. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.09.012 · Cited by 380
Kanasaki, K., Shi, S., Kanasaki, M., He, J., Nagai, T., Nakamura, Y., Ishigaki, Y., Kitada, M., Srivastava, S. P., & Koya, D. (2014) · Diabetes · doi:10.2337/db13-1029 · Cited by 359
Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., García-de-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010145 · Cited by 358
Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
van Bloemendaal, L., ten Kulve, J. S., la Fleur, S. E., Ijzerman, R. G., & Diamant, M. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0414 · Cited by 312
“The role of gastric motility in appetite and satiation regulation and the effects of GLP-1/GLP-1RA on gastric and gut motility has been extensively reviewed (Janssen et al. 2011, Marathe et al. 2011).”
Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
Madsbad, S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12596 · Cited by 305
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302
“Reducing the rate of gastric emptying, however, does not just impact satiety, but also delays the rate of entry of nutrients into the small intestine and their subsequent absorption, which therefore influence postprandial glucose metabolism, hormonal responses, and ultimately enhances GLP-1’s anti-diabetogenic effects…”
BackgroundObata, Y., & Pachnis, V. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.07.044 · Cited by 277
Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity
Maselli, D. B., & Camilleri, M. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_496 · Cited by 248
Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
Jacobsen, L. V., Flint, A., Olsen, A. K., & Ingwersen, S. H. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0343-6 · Cited by 217
“GLP-1 agonists have been reported to slow gastric emptying as a result of reduced gastrointestinal motility [71].”
BackgroundWharton, S., Calanna, S., Davies, M., Dicker, D., Goldman, B., Lingvay, I., Mosenzon, O., Rubino, D. M., Thomsen, M., Wadden, T. A., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14551 · Cited by 200
“Constipation tended to last longer, and may be because of the effects of GLP-1RAs on GI motility.(22) Among the participants who”
BackgroundClinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide
Jalleh, R. J., Plummer, M. P., Marathe, C. S., Umapathysivam, M. M., Quast, D. R., Rayner, C. K., Jones, K. L., Wu, T., Horowitz, M., & Nauck, M. A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae719 · Cited by 157
“This is surprising, since the overall incidence of gastrointestinal adverse events is much higher with the latter class (98).”
Self-citationLorenz, M., Pfeiffer, C., Steinsträßer, A., Becker, R. H. A., Rütten, H., Ruus, P., & Horowitz, M. (2013) · Regulatory Peptides · doi:10.1016/j.regpep.2013.04.001 · Cited by 149
Self-citationLiraglutide and obesity: a review of the data so far
Ladenheim, E. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s58459 · Cited by 146
Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions
Jalleh, R. J., Rayner, C. K., Hausken, T., Jones, K. L., Camilleri, M., & Horowitz, M. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(24)00188-2 · Cited by 144
Self-citationShah, M., Law, J. H., Micheletto, F., Sathananthan, M., Dalla Man, C., Cobelli, C., Rizza, R. A., Camilleri, M., Zinsmeister, A. R., & Vella, A. (2014) · Diabetes · doi:10.2337/db13-0954 · Cited by 138
Fukui, H., Xu, X., & Miwa, H. (2018) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm18071 · Cited by 128
Role of gut microbiota-derived signals in the regulation of gastrointestinal motility
Zheng, Z., Tang, J., Hu, Y., & Zhang, W. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.961703 · Cited by 103
Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity
Yaribeygi, H., Sathyapalan, T., & Sahebkar, A. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116776 · Cited by 102
Glucagon-like peptides 1 and 2 in health and disease: A review
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2013) · Peptides · doi:10.1016/j.peptides.2013.01.014 · Cited by 100
Self-citationEffects of glucagon-like peptide-1 receptor agonists on renal function
Filippatos, T. D., & Elisaf, M. S. (2013) · World Journal of Diabetes · doi:10.4239/wjd.v4.i5.190 · Cited by 97
Adriaenssens, A., Lam, B. Y. H., Billing, L., Skeffington, K., Sewing, S., Reimann, F., & Gribble, F. (2015) · Endocrinology · doi:10.1210/en.2015-1301 · Cited by 88
Pechenov, S., Revell, J., Will, S., Naylor, J., Tyagi, P., Patel, C., Liang, L., Tseng, L., Huang, Y., Rosenbaum, A. I., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-01750-0 · Cited by 77
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Cahen, D. L., & van Raalte, D. H. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12593 · Cited by 74
“Exogenous administration of GLP-1 peptide dosedependently decreases the gastric emptying rate [78,79].”
BackgroundClinical pharmacology of glucagon-like peptide-1 receptor agonists
Sfairopoulos, D. G., Liatis, S., Tigas, S. K., & Liberopoulos, E. N. (2018) · HORMONES · doi:10.1007/s42000-018-0038-0 · Cited by 73
The Regulation of Peripheral Metabolism by Gut-Derived Hormones
Sun, E. W. L., Martin, A. M., Young, R. L., & Keating, D. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00754 · Cited by 71
“There is growing appreciation that a considerable portion of the glucose-lowering effect of GLP-1 is underscored by its inhibitory effect on gastric motility (80– 83) and its glucagonostatic action (84, 85), which are preserved in obese and T2D patients (86, 87).”
BackgroundExploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning
Kim, J. A., & Yoo, H. J. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0242 · Cited by 71
Incretin‐Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes
Faillie, J., Yin, H., Yu, O. H. Y., Herrero, A., Altwegg, R., Renoux, C., & Azoulay, L. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2430 · Cited by 67
“Indeed, increased GLP- 1 action has been shown to inhibit small intestinal motility in both animal and human studies,(10,34) as well as colonic transit in rats.(10,35) In human studies, gastrointestinal transit time was reduced by exendine(939), an inverse agonist Table 3 HRs for intestinal obstruction comparing GLP-…”
BackgroundNora, M. C., Morais, T., Almeida, R., Guimarães, M., & Monteiro, M. P. (2017) · Medicine · doi:10.1097/md.0000000000008859 · Cited by 67
Jalleh, R. J., Marathe, C. S., Rayner, C. K., Jones, K. L., Umapathysivam, M. M., Wu, T., Quast, D. R., Plummer, M. P., Nauck, M. A., & Horowitz, M. (2024) · Endocrinology · doi:10.1210/endocr/bqae155 · Cited by 61
Self-citationGLP-1 based therapies: clinical implications for gastroenterologists
Smits, M. M., van Raalte, D. H., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., & Cahen, D. L. (2016) · Gut · doi:10.1136/gutjnl-2015-310572 · Cited by 61
The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity
Crane, J., & McGowan, B. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315620180 · Cited by 59
Bılgın, E., Venerito, V., & Bogdanos, D. P. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103864 · Cited by 57
The stimulation of GLP-1 secretion and delivery of GLP-1 agonists via nanostructured lipid carriers
Shrestha, N., Bouttefeux, O., Vanvarenberg, K., Lundquist, P., Cuñarro, J., Tovar, S. A., Khodus, G. R., Andersson, E., Keita, Å. V., Dieguez, C. G., et al. (2017) · Nanoscale · doi:10.1039/c7nr07736j · Cited by 56
Nexøe‐Larsen, C. C., Sørensen, P. H., Hausner, H., Agersnap, M., Baekdal, M., Brønden, A., Gustafsson, L. N., Sonne, D. P., Vedtofte, L., Vilsbøll, T., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13420 · Cited by 51
“6 mg dose vs 77 (0-183) minutes with placebo and to 151 (11-240) minutes vs 77 (22-212) minutes at steady-state (no statistical testing was done).”
BackgroundPsaltis, J. P., Marathe, J., Nguyen, M. T., Le, R., Bursill, C. A., Marathe, C. S., Nelson, A. J., & Psaltis, P. J. (2024) · Medicinal Research Reviews · doi:10.1002/med.22070 · Cited by 51
Self-citationMicrobiome, Immunomodulation, and the Neuronal System
Marietta, E. V., Horwath, I. E., & Taneja, V. (2018) · Neurotherapeutics · doi:10.1007/s13311-017-0601-4 · Cited by 49
Nadeem, D., Taye, M., Still, M. D., McShea, S., Satterfield, D., Dove, J. T., Wood, G. C., Addissie, B. D., Diehl, D. L., Johal, A. S., et al. (2024) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2024.04.2900 · Cited by 48
Exogenous glucagon-like peptide 1 reduces contractions in human colon circular muscle
Amato, A., Baldassano, S., Liotta, R., Serio, R., & Mulè, F. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0525 · Cited by 48
Ge, J. J., Wang, D., Song, W., Shen, S., & Ge, W. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01666-6 · Cited by 47
João, A. L., Reis, F., & Fernandes, R. (2016) · Obesity Reviews · doi:10.1111/obr.12421 · Cited by 44
A Review on the Efficacy and Safety of Oral Semaglutide
Niman, S., Hardy, J., Goldfaden, R. F., Reid, J., Sheikh‐Ali, M., SUTTON, D. R., & Choksi, R. R. (2021) · Drugs in R&D · doi:10.1007/s40268-021-00341-8 · Cited by 43
MRI assessment of the postprandial gastrointestinal motility and peptide response in healthy humans
Khalaf, A., Hoad, C. L., Menys, A., Nowak, A., Taylor, S. A., Paparo, S. B., Lingaya, M. R., Falcone, Y., Singh, G., Spiller, R. E., et al. (2017) · Neurogastroenterology & Motility · doi:10.1111/nmo.13182 · Cited by 39
Gastrointestinal autonomic neuropathy in diabetes
Marathe, C. S., Jones, K. L., Wu, T., Rayner, C. K., & Horowitz, M. (2020) · Autonomic Neuroscience · doi:10.1016/j.autneu.2020.102718 · Cited by 38
Self-citationBroide, E., Bloch, O., Ben-Yehudah, G., Cantrell, D., Shirin, H., & Rapoport, M. J. (2013) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155413497586 · Cited by 38
Singh, S., Rahman, S. H., Khan, N., Rajagopal, A., Shafique, N., Tawde, P., Bhardwaj, V., Suresh Kumar, V. C., Aswath, G., Inamdar, S., et al. (2025) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2024.10.011 · Cited by 35
Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges
Zhou, Z., Yi, L., Popławska-Domaszewicz, K., Chaudhuri, К. R., Jankovic, J. J., & Tan, E. K. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107770 · Cited by 35
Åhrén, B., Gautier, J., Berria, R., Stager, W., Aronson, R., & Bailey, C. J. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12290 · Cited by 33
Nreu, B., Dicembrini, I., Tinti, F., Mannucci, E., & Monami, M. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108087 · Cited by 32
Abu‐Freha, N., Yitzhak, A., Shirin, H., Nevo-Shor, A., Abu-Jaffar, J., Abu-Rafe, S., Afianish, Y., Cohen, D. L., & Bermont, A. (2024) · Endoscopy · doi:10.1055/a-2419-3875 · Cited by 32
Drug‐drug interactions in pharmacologic management of gastroparesis
Youssef, A. S., Parkman, H. P., & Nagar, S. (2015) · Neurogastroenterology & Motility · doi:10.1111/nmo.12614 · Cited by 31
Pizzimenti, V., Giandalia, A., Cucinotta, D., Russo, G. T., Smits, M., Cutroneo, P. M., & Trifirò, G. (2016) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12373 · Cited by 30
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Pieters, I. C., Cahen, D. L., Diamant, M., & van Raalte, D. H. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-009579 · Cited by 30
Tong, Y., Huang, J., Chen, Y., Tu, M., & Wang, W. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1176206 · Cited by 27
GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation
Migliorisi, G., Gabbiadini, R., Buono, A. D., Ferraris, M., Privitera, G., Petronio, L., Bertoli, P., Bezzio, C., & Armuzzi, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1610368 · Cited by 26
Mutanen, A., & Pakarinen, M. P. (2016) · Clinical Nutrition · doi:10.1016/j.clnu.2016.09.002 · Cited by 25
Gut-Based Strategies to Reduce Postprandial Glycaemia in Type 2 Diabetes
Kamruzzaman, M., Horowitz, M., Jones, K. L., & Marathe, C. S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.661877 · Cited by 24
Self-citationResearch progress of GLP-1RAs in the treatment of type 2 diabetes mellitus
He, X., Zhao, W., Li, P., Zhang, Y., Li, G., Su, H., Lu, B., & Pang, Z. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1483792 · Cited by 21
Nielsen, J., Friedman, S., Nørgård, B. M., Knudsen, T., Kjeldsen, J., & Wod, M. (2025) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izae276 · Cited by 20
The efficacy and safety of exenatide once weekly in patients with type 2 diabetes
Heimbürger, S. M. N., Brønden, A., Johansen, N. J., Dejgaard, T. F., Vilsbøll, T., & Knop, F. K. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1571040 · Cited by 20
Husník, R., Gaschen, F. P., Fletcher, J. M., & Gaschen, L. E. (2020) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.15787 · Cited by 19
Zheng, K., Azhie, A., You, X., Naghibzadeh, M., Tan, E. X. X., Naimimohasses, S., Sridhar, V. S., Gupta, S., Chen, S., Dash, S., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15769 · Cited by 19
Gastrointestinal hormone-mediated beneficial bioactivities of bitter polyphenols
Osakabe, N., Ohmoto, M., Shimizu, T., Iida, N., Fushimi, T., Fujii, Y., Abe, K., & Calabrese, V. (2024) · Food Bioscience · doi:10.1016/j.fbio.2024.104550 · Cited by 18
Dipeptidyl peptidase-4 inhibitors have adverse effects for the proliferation of human T cells
Kitagawa, N., Hamaguchi, M., Majima, S., Fukuda, T., Kimura, T., Hashimoto, Y., Tanaka, M., Yamazaki, M., Nakamura, N., & Fukui, M. (2018) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.17-64 · Cited by 17
Three ileus cases associated with the use of dipeptidyl peptidase‐4 inhibitors in diabetic patients
Kanasaki, K., Konishi, K., Hayashi, R., Shiroeda, H., Nomura, T., Nakagawa, A., Nagai, T., Takeda‐Watanabe, A., Ito, H., Tsuda, S., et al. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12095 · Cited by 16
Novel insights into the effects of diabetes on gastric motility
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1129898 · Cited by 16
Self-citationHompesch, M., Kang, J., Han, O., TRAUTMANN, M. E., SORLI, C. H., Ogbaa, I., Stewart, J. A., & Morrow, L. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002208 · Cited by 15
Carris, N. W., Wallace, S., DuCoin, C. G., Mhaskar, R. S., Stern, M., & Bunnell, B. E. (2024) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2023-0464 · Cited by 13
Huang, X., Wu, M., Huang, B., & Zhang, Y. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1509947 · Cited by 12
Takahashi, K., Fujita, H., Fujita, N., Takahashi, Y., Kato, S., Shimizu, T., Suganuma, Y., Sato, T. K., Waki, H., & Yamada, Y. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01283-3 · Cited by 12
The expanding role of semaglutide: beyond glycemic control
Zarei, M., Sabetkasaei, M., Mozafari, M., & Zaeri, S. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01663-z · Cited by 11
Abdelrahman, R. M., Musa, T. H., Arbab, I. A., Ahmed, E. O., Gasmallah, S. I., Jalal, M., Mgbechidinma, C. L., & Ahmed, W. R. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100699 · Cited by 11
Alqifari, S. F., Komi, O. A., Esmail, A., Alkhawami, K., Yousri, S., Muqresh, M. A., Alharbi, N., Khojah, A. A. A., Aljabri, A. M., Allahham, A., et al. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i3.331 · Cited by 11
Dietary Free Amino Acids and the Gastric Phase of Digestion
Zolotarev, V. A. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990581 · Cited by 11
Liu, M., Fan, G., Meng, L., Yang, K., & Liu, H. (2024) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2300343 · Cited by 10
Liefferinge, E. V., Muller, M., Noten, N. V., Degroote, J., Niknafs, S., Roura, E., & Michiels, J. (2021) · Animals · doi:10.3390/ani11082262 · Cited by 10
Grasset, E., Briand, F., Virgilio, N., Schön, C., Wilhelm, M. G., Cudennec, B., Ravallec, R., Aboubacar, H., Vleminckx, S., Prawitt, J., et al. (2024) · Food Science & Nutrition · doi:10.1002/fsn3.4538 · Cited by 9
Naimi, R. M., Hvistendahl, M., Thomassen, L. M., Johnsen, H., Christiansen, C. B., Holst, J. J., Hartmann, B., & Jeppesen, P. B. (2021) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2021-000604 · Cited by 9
Winkler, G., Hajós, P., & Kis, J. T. (2019) · Orvosi Hetilap · doi:10.1556/650.2019.31615 · Cited by 8
Gastrointestinal disorders in diabetes
Marathe, C. S., Rayner, C. K., Wu, T., Jones, K. L., & Horowitz, M. (2020) · MDText.com, Inc. eBooks · Cited by 8
Self-citationFujita, Y., Kitamura, T., Otsuki, M., Tamada, D., Tabuchi, Y., Kozawa, J., Yasuda, T., Okita, K., Imagawa, A., Kaneto, H., et al. (2012) · Diabetes Care · doi:10.2337/dc12-1499 · Cited by 8
Bennett, D., Davé, S., Sakaguchi, M., Chang, C., & Dolin, P. (2016) · Diabetology International · doi:10.1007/s13340-016-0261-3 · Cited by 8
Guzzardi, M. A., Rosa, F. L., Campani, D., Insilla, A. C., Nannipieri, M., Brunetto, M. R., Bonino, F., & Iozzo, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052659 · Cited by 7
Lee, S. P., Kuo, F. Y., Cheng, J., & Wu, M. C. (2019) · Archives of Medical Science · doi:10.5114/aoms.2019.86938 · Cited by 6
Panenteric Transit Times and Contractile Activity in Diabetic Gastroenteropathy
Kornum, D. S., Brock, C., Okdahl, T., Bertoli, D., Kufaishi, H., Wegeberg, A., Høyer, K. L., Mark, E. B., Brock, B., Hansen, C. S., et al. (2025) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm24126 · Cited by 5
Acute Kidney and Liver Injury Associated With Low-Dose Liraglutide in an Obese Adolescent Patient
Komargodski, R., Wittenberg, A., Bahat, H., & Rachmiel, M. (2024) · PEDIATRICS · doi:10.1542/peds.2023-063719 · Cited by 5
Mazze, R. S., Strock, E. S., Monk, A. M., Murphy, M. M., Xi, M. X., & Bergenstal, R. M. (2013) · Endocrine Practice · doi:10.4158/ep12337.or · Cited by 5
Stomach ‘tastes’ the food and adjusts its emptying: A neurophysiological hypothesis (Review)
Papacocea, T. M., Papacocea, R. I., Rădoi, M. P., Pițuru, S., & Bălan, D. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8874 · Cited by 5
Long-term complications of significant weight loss: lessons learned from bariatric surgery
Harrington, S., Kang, S., Telesca, L., COHEN, R. V., & le Roux, C. W. (2023) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2023.46 · Cited by 5
Alkabbani, W., Crisafulli, S., Paik, J. M., Tavakkoli, A., Bykov, K., Glynn, R. J., Wexler, D. J., & Patorno, E. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70963 · Cited by 4
Gniaź, N., Górska, A., Grela, W., Niewiadomska, J., Furtak, D., Tulej, D., Głogowska, P., Dziedzic, A., Marciniuk, D., & Marko, N. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.75.56672 · Cited by 4
Lorenz, N., Stauffer, J. R., Abouafech, A., Mourad, A., & Bray, K. (2025) · Cureus · doi:10.7759/cureus.90657 · Cited by 4
Posada, M. M., Schneck, K. B., Morse, B. L., Rougée, L. R. A., Tham, L. S., Rehmel, J., Thompson, B., Stamatis, S. D., Hall, S. D., & Dickinson, G. L. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70101 · Cited by 4
Constipation and glycemic control
Conway, R. B. N., Peltier, A., & Figaro, M. K. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107799 · Cited by 4
Theodorakis, N., Kreouzi, M., & Nikolaou, M. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10506-1 · Cited by 3
Mokrani, M., Brochot, A., & Urdaci, M. C. (2025) · Antioxidants · doi:10.3390/antiox14121484 · Cited by 3
Glucagon-like peptide-1 drugs, gastrointestinal function and critical illness
Nadkarni, A., Deane, A. M., & Plummer, M. P. (2026) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000001376 · Cited by 3
Hoekx, C. A., Straat, M. E., Bizino, M. B., van Eyk, H. J., Lamb, H. J., Smit, J. W. A., Jazet, I. M., de Jager, S. C. A., Boon, M. R., & Martínez‐Téllez, B. (2024) · Experimental Physiology · doi:10.1113/ep091815 · Cited by 3
Bahdi, F., Bachu, V. S., Aldzhyan, V., Villanueva, G. P., Liang, S., Manandhar, A., Tripathi, P. V., Connolly, L. S., Ghassemi, K. A., Issa, D., et al. (2026) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002414 · Cited by 3
Morales, J., & Assumpcao‐Morales, M. (2019) · Journal of Cardiology & Current Research · doi:10.15406/jccr.2019.12.00450 · Cited by 3
Metadata
- Authors
- Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M.
- Affiliations
- Royal Adelaide Hospital (AU)
- Corresponding author
- Rayner, Christopher K.
- Venue
- Experimental Diabetes Research
- Publisher
- Wiley
- Published
- 2011
- Volume
- 2011
- Pages
- 1-10
- ISSN
- 1687-5214 (ISSN-L)
- 1687-5303
- PMC
- PMC3124003
- OpenAlex
- W2065444806
- Cited by
- 138
- References
- 112
- Citations by year
- 2026: 16 · 2025: 18 · 2024: 20 · 2023: 3 · 2022: 6 · 2021: 11 · 2020: 11 · 2019: 10 · 2018: 6 · 2017: 3 · 2016: 6 · 2015: 9 · 2014: 6 · 2013: 12 · 2012: 1
- FWCI
- 4.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Experimental Diabetes Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UniSA Research Outputs Repository (University of South Australia) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- glucagon-like peptide-1, incretin-based therapy, gastrointestinal motility, enterogastrone, type 2 diabetes, anti-obesity, gastric emptying, gastric acid secretion
- MeSH terms
- Animals, Diabetes Mellitus, Type 2, Gastrointestinal Hormones, Gastrointestinal Motility, Humans, Movement, Peptides, Gastrointestinal Tract, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.